The issuance of a new patent generally strengthens a company's competitive position and can lead to positive investor sentiment. For Dermata, the new patent in Japan for its DMT410 program could protect its potential revenue stream from this treatment, assuming successful development and commercialization. This news is likely to be viewed positively by investors in the short term, leading to an increase in the stock price.